PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 120 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $0 | – | 0 | – | 0.00% | – |
Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Q4 2020 | $0 | – | 0 | – | 0.00% | – |
Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q4 2019 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | – |
Q3 2019 | $2,000 | +100.0% | 300 | -12.0% | 0.00% | – |
Q4 2018 | $1,000 | -50.0% | 341 | 0.0% | 0.00% | – |
Q3 2018 | $2,000 | -33.3% | 341 | 0.0% | 0.00% | – |
Q2 2018 | $3,000 | +50.0% | 341 | 0.0% | 0.00% | – |
Q1 2018 | $2,000 | 0.0% | 341 | 0.0% | 0.00% | – |
Q4 2017 | $2,000 | -33.3% | 341 | -24.4% | 0.00% | – |
Q3 2017 | $3,000 | 0.0% | 451 | 0.0% | 0.00% | – |
Q2 2017 | $3,000 | -25.0% | 451 | 0.0% | 0.00% | – |
Q1 2017 | $4,000 | 0.0% | 451 | 0.0% | 0.00% | – |
Q4 2016 | $4,000 | +33.3% | 451 | +10.0% | 0.00% | – |
Q3 2016 | $3,000 | +50.0% | 410 | 0.0% | 0.00% | – |
Q2 2016 | $2,000 | -33.3% | 410 | 0.0% | 0.00% | – |
Q4 2015 | $3,000 | – | 410 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |